STAT News

OCTOBER 19, 2022

1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months , Reuters notes. Omicron-tailored  Omicron-tailored shots by Pfizer and Moderna are already authorized by regulators in several countries. 5 subvariants of Omicron.

Immune Response 98

Immune Response Scientist Vaccination Vaccine 98

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “With new variants – like Omicron and B.1.640.2

Protein 126

Protein Vaccination Vaccine Immune Response 126

Drug Discovery Today

APRIL 5, 2022

Researchers delve into the inner workings of the antibody immune response, finding key differences in the metabolism of two closely related immune cell subsets.

Immune Response 45

Immune Response Regulation Antibody Research 45

pharmaphorum

AUGUST 11, 2022

Figures from the UK Office for National Statistics (ONS) have revealed that the number of people with higher levels of COVID-19 antibodies in their blood is declining quickly – leading to calls for booster vaccination campaigns to be started as soon as possible. 1 Omicron subvariant – are currently under review at the regulator.

Antibody 52

Antibody Immune Response Vaccination Vaccine 52

pharmaphorum

JULY 9, 2021

With the COVID-19 delta variant has become the dominant strain circulating in the US, Pfizer and BioNTech have said they will ask the FDA and other regulators to approve a third dose of their Comirnaty vaccine to guard against a winter surge in cases. .

Vaccination 98

Vaccination Vaccine Antibody Immune Response 98

Find Me Cure

APRIL 23, 2020

This means that in order for herd immunity to work, 50-70% of the world population needs to get infected and then develop antibodies. . But another huge question mark here is if it’s even possible for people to become immune for long enough for this theory to even work. Thus, herd immunity wouldn’t work in this scenario.

Immune Response 117

Immune Response Antibody Scientist Development 117

pharmaphorum

AUGUST 16, 2021

The two companies have submitted data from a phase 1 trial in support of the booster dose to the US regulator, and will follow that with filings in Europe and elsewhere in the world in the coming weeks.

FDA Approval 105

FDA Approval Vaccination Vaccine Antibody 105

pharmaphorum

DECEMBER 11, 2020

Interim results from a phase 1/2 clinical trial show the immune response from Sanofi/GSK’s vaccine produced a lower immune response in older adults. While antibody levels were comparable to those seen in recovering COVID-19 patients in adults aged 18-49, the response was lower in older adults.

Immune Response 73

Immune Response Trials Vaccination Vaccine 73

The Pharma Data

MARCH 25, 2021

today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. Source link:[link].

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JULY 29, 2022

This data has been shared with regulators, including the US Food and Drug Administration (FDA), and a request for US Emergency Use Authorisation (EUA) is planned. Bivalent vaccines work by stimulating an immune response against two different antigens, whereas monovalent vaccines only target one antigen. 1 sub-lineage on 19 July.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial. At six months, 29.5 Changing the Face of Malaria.

Vaccine 105

Vaccine Vaccination Immune Response Trials 105

pharmaphorum

SEPTEMBER 25, 2020

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regulator. In animal models, neutralising DKK1 has been shown to activate an innate immune response against malignant cells.

Immune Response 72

Immune Response Trials Drugs Containment 72

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer.

Immune Response 115

Immune Response Development Research Protein 115

pharmaphorum

FEBRUARY 18, 2021

Mutations may alter neutralisation by affecting spike function rather than antigen response and its also unclear from this study how the T-cell response is affected. The body’s immune response to the coronavirus is not limited to antibodies with CD8+ T-cells also playing roll combating infections.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

pharmaphorum

APRIL 14, 2022

billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL). Two years after signing a $3.9 Analysts at Jefferies have previously said they think epcoritamab could become a $1.5

Licensing 64

Licensing Licensing Immune Response Antibody 64

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Vaccination 64

Vaccination Vaccine Immune Response Gene Sequencing 64

pharmaphorum

AUGUST 24, 2020

Forbius has also been working on some other targets, including an EGFR-targeting antibody-drug conjugate (ADC), but these will be spun into another company that will remain in the hands of its current shareholders.

Immune Response 59

Immune Response Antibody Drugs Development 59

XTalks

JULY 26, 2021

Related: US Regulators Recommend Pause on J&J’s COVID-19 Vaccine, But Just as a Precaution. The lab studies involved assessing the activity of neutralizing antibodies from convalescent sera against SARS-CoV-2 and various variants. The European Medicines Agency (EMA) did the same, citing it as a “very rare side effect.”.

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98

pharmaphorum

MARCH 28, 2022

GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus. 2, and would be sharing these data with regulators around the world. 2 subvariant of Omicron. Previously, when the original BA.1

Antibody 52

Antibody Immune Response Regulation Sales 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response. population.

Immune Response 52

Immune Response Protein Medicine Genetics 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

JUNE 23, 2022

Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against the Omicron subvariants BA.4 According to a Moderna statement , the booster stimulated a greater than five-fold increase in neutralising antibodies against Omicron BA.4 1) Why is this important?

Vaccination 69

Vaccination Vaccine Immune Response Protein 69

pharmaphorum

JANUARY 27, 2021

The companies said in December they were having to rethink the antigen formulation of their vaccine after it failed to produce the desired immune response in people aged 50 years and older, although results were more favourable in younger age groups. This is expected to delay availability of the vaccine until later this year.

Vaccination 69

Vaccination Vaccine Immune Response Manufacturing 69

XTalks

JULY 2, 2021

This is because the processes that maintain the uterine lining, including the placenta, during pregnancy are different than those that regulate the normal menstrual cycle. However, the similarity between the two proteins is not great enough for anti-spike antibodies to cross-react with placental syncytin-1.

Vaccine 105

Vaccine Vaccination Protein Immune Response 105

pharmaphorum

AUGUST 31, 2021

The move follows phase 1/2 results with SK bio’s GBP510, which found that it stimulated neutralising antibodies against SARS-CoV-2 in all 80 recipients, with no safety issues recorded. Neutralising antibody titres in the blood were five to eight times higher than people who recovered from COVID-19.

Vaccine 59

Vaccine Vaccination Protein Immune Response 59

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. And if the results are positive, the companies expect to seek approval from regulators in the fourth quarter. 14, 2020 ). 2 infection.

Vaccination 40

Vaccination Vaccine Immune Response RNA 40

pharmaphorum

SEPTEMBER 29, 2020

The US drugs regulator has placed the phase 2/3 trial of INO-4800 on partial clinical hold while it seeks answers from the company about the DNA-based vaccine as well as the device used to deliver the shot to patients in the study.

Vaccination 52

Vaccination Vaccine Trials DNA 52

The Pharma Data

JANUARY 21, 2021

.” But the Pfizer and Moderna vaccines are designed to not only target the spike protein, but to promote the creation of antibodies that will attack it in several different ways, Salvatore said. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

pharmaphorum

OCTOBER 6, 2020

The announcement comes just days after the regulator said its CHMP scientific committee had begun to look at the first batch of data from AZ’s rival. These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

pharmaphorum

APRIL 27, 2021

Participants showed high titres of malaria-specific anti-NANP antibodies 28 days after the third vaccination, which were almost doubled with the higher adjuvant dose. The Serum Institute of India has manufactured the malaria vaccine and says it could deliver more than 200 million doses as soon as it is approved by regulators.

Vaccine 52

Vaccine Vaccination Immune Response Trials 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

APRIL 6, 2021

According to Channel 4 news, two senior sources have said the regulator is being urged to offer other vaccines to younger people because of a possible link between the AZ jab and blood clots, in particular a rare condition known as cerebral venous sinus thrombosis (CVST).

Vaccine 80

Vaccine Vaccination Immune Response Manufacturing 80

pharmaphorum

JANUARY 7, 2021

Used with widely available PET scan technology, ImaginAb’s technology allows doctors to track the T-cell immune response to cancer in real time and it has already picked up a multi-party deal involving Pfizer, AstraZeneca and Takeda.

Immune Response 53

Immune Response Doctors Doctor Pharma Companies 53

The Pharma Data

NOVEMBER 17, 2020

t for the treatment of autoimmune diseases , which occur when the body’s immune system attacks its own cells and tissues as foreign invaders. . While the antibody responsible for immune-mediated diseases is yet to be identified, they are thought to be regulated by an aberrant immune response.

Immune Response 52

Immune Response Licensing Licensing Sales 52

Delveinsight

JANUARY 22, 2021

There are newer agents coming to the market, for instance, Fc receptor via monoclonal IgG antibodies mechanism, BTK [Bruton tyrosine kinase] inhibition, and so on, however, the real challenge lies in the compliance in terms of patients perspectives such as cost and tolerance.

Marketing 65

Marketing Drugs Antibody Compliance 65